Given the above, the attenuated or diminished anemia-improving effect of SGLT2 inhibitors in this study in patients with nephrotic range proteinuria may be due to the urinary losses of EPO, transferrin, and/or iron, which are considered to be crucial for the promotion of erythropoiesis by SGLT2 inhibitors. The gene discussed is TF; the disease is anemia.